Kyntra Bio (LTS:0IL8) Operating Margin %: -369.07% (As of Mar. 2026)


LTS:0IL8 Kyntra Bio Inc LTS:0IL8
52 GF Score
Price $6.86
GF Value $5.68
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Kyntra Bio Operating Margin %?

Kyntra Bio LTS:0IL8 52 Operating Margin % is -369.07% as of Mar. 2026. GuruFocus rates LTS:0IL8 with a GF Score™ of 52/100 and a GF Value™ of $5.68 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 945 Biotechnology companies, Kyntra Bio ranks worse than 72.49% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Kyntra Bio's Operating Income for the three months ended in Mar. 2026 was $-13.80 Mil. Kyntra Bio's Revenue for the three months ended in Mar. 2026 was $3.74 Mil. Therefore, Kyntra Bio's Operating Margin % for the quarter that ended in Mar. 2026 was -369.07%.

Warning Sign:

Kyntra Bio Inc operating margin has been in a 5-year decline. The average rate of decline per year is -50.5%.

The historical rank and industry rank for Kyntra Bio's Operating Margin % or its related term are showing as below:

LTS:0IL8' s Operating Margin % Range Over the Past 10 Years
Min: -704.07   Med: -115.73   Max: -27.32
Current: -596.1


LTS:0IL8's Operating Margin % is ranked worse than
72.49% of 945 companies
in the Biotechnology industry
Industry Median: -86.89 vs LTS:0IL8: -596.10

Kyntra Bio's 5-Year Average Operating Margin % Growth Rate was -50.50% per year.

Kyntra Bio's Operating Income for the three months ended in Mar. 2026 was $-13.80 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was $-44.34 Mil.


Kyntra Bio  (LTS:0IL8) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Kyntra Bio Operating Margin % Related Terms


Kyntra Bio Operating Margin % Historical Data

* Premium members only.

The historical data trend for Kyntra Bio's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kyntra Bio Operating Margin % Chart

Kyntra Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -122.62 -213.90 -662.60 -442.13 -704.07

Kyntra Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -540.12 -864.91 -499.07 -1,058.65 -369.07

LTS:0IL8 vs SER, SNSE, PVCT: Operating Margin % Comparison

For the Biotechnology subindustry, Kyntra Bio's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kyntra Bio Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kyntra Bio's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Kyntra Bio's Operating Margin % falls into.


LTS:0IL8
52GF Score
Kyntra Bio Inc LTS:0IL8
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kyntra Bio Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Kyntra Bio's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-45.342 / 6.44
=-704.07 %

Kyntra Bio's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=-13.796 / 3.738
=-369.07 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of -369.07% mean?
Kyntra Bio (LTS:0IL8) has a Operating Margin % of -369.07% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Kyntra Bio and its competitors. According to the industry distribution chart, Kyntra Bio ranks #685 out of 945 companies in the Biotechnology industry, placing it in the top 72.5%.
Is Kyntra Bio's Operating Margin % too high?
Kyntra Bio's current Operating Margin % is -369.07%. Based on the distribution chart, Kyntra Bio ranks #685 out of 945 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Kyntra Bio has a GF Score™ of 52/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kyntra Bio's Operating Margin % compare to SER and SNSE?
According to the Biotechnology industry distribution chart, Kyntra Bio ranks #685 out of 945 companies for Operating Margin %. This places Kyntra Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Kyntra Bio and its competitors. Kyntra Bio's current Operating Margin % is -369.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyntra Bio stock overvalued right now?
Based on GuruFocus' analysis, Kyntra Bio (LTS:0IL8) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.68, compared to a current price of $6.86 — trading 20.7% above its estimated fair value. The current Operating Margin % is -369.07%. Kyntra Bio's overall GF Score™ is 52/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Kyntra Bio (LTS:0IL8), the current Operating Margin % is -369.07% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kyntra Bio (LTS:0IL8) Overvalued in 2026?

Based on GuruFocus' analysis, Kyntra Bio stock appears to be overvalued. The current stock price of $6.86 is trading 20.7% above its estimated GF Value™ of $5.68. GuruFocus considers Kyntra Bio to be Modestly Overvalued.

Key valuation signals for LTS:0IL8:

  • Operating Margin %: -369.07%
  • GF Value™: $5.68 vs. price of $6.86 (20.7% above fair value)
  • GF Score™: 52/100 with 8 warning signs

No single metric tells the full story. See the LTS:0IL8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kyntra Bio Business Description

Address 350 Bay Street, Suite 100, No. 6009, San Francisco, CA, USA, 94133
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
52GF Score

Get the complete analysis for LTS:0IL8

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.86
Price
$5.68
GF Value